

Promising Biomarkers in Liquid Biopsy of Cancer

Guest Editor:

Message from the Guest Editor

Dr. Galatea Kallergi

Department of Biology, University
of Patras, 26504 Patras, Greece

Deadline for manuscript
submissions:


closed (31 January 2023)

Targeted therapies have revolutionized the treatment of cancer. While these targets change during disease evolution or in response to therapy, it is extremely important to follow these alterations so that patients receive the appropriate treatment at each stage of the disease. Liquid biopsy (LB) can easily address this problem without painful interventions. LB is also an important tool for finding new therapeutic targets as well as prognostic factors for cancer patients. The main constituents of LB are circulating tumor cells (CTCs), ctDNA, exosomes, and microRNAs. Evaluation of one or more of these factors may provide useful information. Many studies have shown that specific CTC subtypes are much more important for prediction or prognosis compared to simple enumeration of total CTCs. On the other hand, the identification of specific mutations in ctDNA has also been shown to be a valuable predictive factor for specific treatments, such as EGFR targeted therapies

In this Special Issue we will focus on new biomarkers in every aspect of LB that can be used for prognosis, prediction to treatment or presenting new therapeutic targets.

Dr. Galatea Kallergi
Guest Editor





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic
Oncology and Reproductive
Medicine, The University of Texas
MD Anderson Cancer Center,
Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)

Contact Us

Cancers Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/cancers
cancers@mdpi.com
[X@Cancers_MDPI](https://twitter.com/Cancers_MDPI)